Redmile Group, Llc

Institutional manager — quarterly 13F holdings, Q ending 2026-03-31

Reported value
$1.51B
Q ending 2026-03-31
Prior quarter
$1.36B
Q ending 2025-12-31
Change
+11.2% QoQ · +42.7% YoY
Positions
35
reported holdings

Largest positions

All 35 reported positions, Q ending 2026-03-31. A manager can hold shares, calls and puts on the same security at once — such positions are listed as separate rows. Type: Shares = common stock, Put/Call = option positions (valued at the underlying), Principal = debt. Tickers link to stock pages where covered.
HoldingTickerTypeValueShares
Scholar Rock Hldg CorpSRRKShares$445.7M9.1M
Krystal Biotech IncKRYSShares$174.0M674K
Stoke Therapeutics IncSTOKShares$135.6M4.2M
Immunome IncIMNMShares$121.6M5.6M
Nurix Therapeutics IncNRIXShares$119.9M7.7M
Annexon IncANNXShares$80.6M14.5M
Adc Therapeutics SaShares$58.0M15.5M
Regenxbio IncRGNXShares$36.6M4.4M
Shattuck Labs IncSTTKShares$35.6M5.5M
Beam Therapeutics IncBEAMShares$29.5M1.2M
Neurogene IncNGNEShares$29.4M1.5M
Cogent Biosciences IncCOGTShares$26.5M688K
Absci CorporationABSIShares$24.8M8.3M
Ideaya Biosciences IncIDYAShares$17.4M521K
Alx Oncology Hldgs IncALXOShares$16.0M8.0M
Fate Therapeutics IncFATEShares$15.4M12.9M
Xenon Pharmaceuticals IncXENEShares$15.3M263K
Solid Biosciences IncSLDBShares$14.5M2.0M
Nuvation Bio IncNUVBShares$13.5M3.2M
Zymeworks IncZYMEShares$12.3M492K
Silence Therapeutics PlcSLNShares$11.4M2.2M
Dbv Technologies S ADBVTShares$10.3M491K
Biomarin Pharmaceutical IncBMRNShares$9.8M174K
Celldex Therapeutics Inc NewCLDXShares$8.3M262K
Ceribell IncCBLLShares$7.1M387K
Livanova PlcShares$6.9M108K
Establishment Labs Hldgs IncShares$5.9M103K
Prime Medicine IncPRMEShares$5.5M1.6M
Oric Pharmaceuticals IncORICShares$5.3M416K
Eupraxia Pharmaceuticals IncEPRXShares$5.1M700K
Ardelyx IncARDXShares$4.4M733K
Invivyd IncIVVDShares$3.4M2.6M
Atara Biotherapeutics IncATRAShares$2.1M442K
Agomab Therapeutics NvAGMBShares$1.6M156K
Pliant Therapeutics IncPLRXShares$973K772K

Values as reported in public regulatory filings (USD); holdings are reported quarterly, up to 45 days after quarter end, and may contain reporting errors. Nothing here is investment advice.